(PRWEB) September 11, 2012
According to an article appearing in the Journal of the American Medical Association prepared by two drug-safety experts, the U.S. Food and Drug Administration’s efforts to hasten the availability of new drugs for stroke prevention, cancer, and multiple sclerosis resulted in the approval of drugs that carry very high risks to those who take them.
Among these drugs is the blood thinner Pradaxa. Pradaxa, a member of the the direct thrombin inhibitors class of drugs, is an anticoagulant (blood-thinning) medication. It is prescribed to prevent strokes and to treat serious blood clots. The drug’s side effects, however, range from nausea to serious cases of dizziness, bleeding gums, and the expectoration of blood.
The authors of the JAMA study address the bleeding risk associated with Pradaxa and note that “no antidote is available for use in bleeding emergencies” caused by the drug.
The Rottenstein Law Group maintains a Pradaxa Lawsuit Information Center to provide comprehensive information to the public about specific dangerous drugs and defective medical products. Those who wish to learn about the dangers of Pradaxa and the utility of legal action should visit http://www.rotlaw.com/pradaxa/. (Attorney advertising. Prior results do not guarantee a similar outcome.)
About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients in consumer product injury, mass tort, and class action lawsuits in a compassionate manner.
Contact:
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
1259 Veeder Drive
Hewlett NY 11557
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle(at)rotlaw(dot)com
We're here to help.
Call 1-866-640-6397
©Copyright 1997-, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
